Coma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Coma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study to evaluate the effect of methylphenidate hydrochloride on the time to wake up in patients in a coma due to acute brain injury https://clinicaltrials.eu/trial/study-to-evaluate-the-effect-of-methylphenidate-hydrochloride-on-the-time-to-wake-up-in-patients-in-a-coma-due-to-acute-brain-injury/ Thu, 30 Apr 2026 13:08:55 +0000 https://clinicaltrials.eu/trial/study-to-evaluate-the-effect-of-methylphenidate-hydrochloride-on-the-time-to-wake-up-in-patients-in-a-coma-due-to-acute-brain-injury/ This study focuses on individuals experiencing a coma caused by an acute brain injury, which is a sudden and severe damage to the brain. The purpose of the study is to see if a specific medication can help patients wake up sooner. The treatment being tested is methylphenidate, which is given by mouth every day. Some participants will receive the active medication, while others will receive a placebo.

During the trial, participants are assigned to different groups to compare the effects of the medication against the placebo. The process involves monitoring how long it takes for a person to show signs of regained consciousness, which is the ability to be awake and aware of their surroundings. The study tracks how quickly patients respond to the treatment and observes their overall recovery and health status during their stay in the intensive care unit.

]]> Study of anti-seizure drug combination in comatose patients with status epilepticus after cardiac arrest https://clinicaltrials.eu/trial/study-on-anti-seizure-treatment-with-esketamine-lorazepam-and-midazolam-for-comatose-patients-after-cardiac-arrest-with-status-epilepticus/ Wed, 29 Apr 2026 15:04:12 +0000 https://clinicaltrials.eu/trial/study-on-anti-seizure-treatment-with-esketamine-lorazepam-and-midazolam-for-comatose-patients-after-cardiac-arrest-with-status-epilepticus/ This study focuses on patients who experience status epilepticus (a severe form of continuous seizures) after cardiac arrest and cardiopulmonary resuscitation. The study aims to determine if treating seizures with medications improves recovery in unconscious patients who have survived cardiac arrest.

The study uses several anti-seizure medications administered through a vein, including diazepam, midazolam, lorazepam, propofol, esketamine, lacosamide, levetiracetam, and sodium valproate. These medications are given in a step-by-step approach to stop the seizure activity that is detected by brain wave monitoring.

The research will compare patients who receive seizure treatment with those who do not receive treatment. The main focus is on how well patients recover their ability to function in daily life six months after their cardiac arrest. The study will also look at the cost-effectiveness of the treatment approach.

]]> Study on the Effects of Sodium Lactate and Electrolyte Solution in Comatose Patients After Cardiac Arrest https://clinicaltrials.eu/trial/study-on-the-effects-of-sodium-lactate-and-electrolyte-solution-in-comatose-patients-after-cardiac-arrest/ Wed, 29 Apr 2026 14:59:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-sodium-lactate-and-electrolyte-solution-in-comatose-patients-after-cardiac-arrest/ This clinical trial is focused on studying the effects of a treatment for patients who have experienced a cardiac arrest, which is when the heart suddenly stops beating. After such an event, patients may suffer from post-anoxic brain injury, a type of brain damage that occurs due to a lack of oxygen, and may fall into a coma. The trial aims to evaluate the effectiveness of a treatment using a solution called SODIO LATTATO MONICO, which contains sodium lactate, to help reduce brain injury in patients who are comatose after cardiac arrest.

The study will involve administering the treatment through an intravenous infusion, which means the solution is given directly into a vein. Another solution, Plasmalyte A Viaflo, which contains a mix of electrolytes like magnesium chloride hexahydrate, potassium chloride, sodium chloride, sodium acetate trihydrate, and sodium gluconate, may also be used. The purpose of the study is to see if these treatments can help improve outcomes for patients by decreasing the extent of brain injury after a cardiac arrest.

Participants in the study will receive the treatment for a short period, and their progress will be monitored over time. The study will look at various outcomes, such as the level of certain proteins in the blood that indicate brain injury, the patient’s recovery in terms of brain function, and their overall health status during their stay in the hospital. The goal is to gather information that could lead to better treatments for people who have suffered a cardiac arrest and are in a coma.

]]> Study on Apomorphine and Psilocybin for Recovery in Coma Patients with Acute Brain Injury https://clinicaltrials.eu/trial/study-on-apomorphine-and-psilocybin-for-recovery-in-coma-patients-with-acute-brain-injury/ Wed, 29 Apr 2026 14:29:01 +0000 https://clinicaltrials.eu/trial/study-on-apomorphine-and-psilocybin-for-recovery-in-coma-patients-with-acute-brain-injury/ This clinical trial is focused on studying treatments for patients who are in a coma or have other consciousness disorders due to sudden brain injuries. The study will explore the use of two treatments: Apomorphine, which is a medication often used to treat Parkinson’s disease, and Psilocybin, a compound found in certain mushrooms that is being researched for its potential effects on the brain. The purpose of the study is to determine the safety of these treatments in patients who are unresponsive and in the intensive care unit (ICU) due to acute brain injury.

During the study, patients will receive either Apomorphine or Psilocybin to see if these treatments can help improve their level of consciousness. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects. The study will monitor how quickly patients wake up within 30 days and will also look at other factors like eye response and brain activity. The study aims to find the right dose that is safe for patients.

The trial will last for a period of time, with regular check-ups to assess the patients’ progress. The researchers will also evaluate the patients’ overall health and any potential side effects of the treatments. The goal is to gather information that could help improve recovery for patients with severe brain injuries in the future.

]]> Study on Psilocybin and Apomorphine for Improving Consciousness in Patients with Coma and Brain Injury https://clinicaltrials.eu/trial/study-on-psilocybin-and-apomorphine-for-improving-consciousness-in-patients-with-coma-and-brain-injury/ Wed, 29 Apr 2026 14:26:03 +0000 https://clinicaltrials.eu/trial/study-on-psilocybin-and-apomorphine-for-improving-consciousness-in-patients-with-coma-and-brain-injury/ This clinical trial is focused on patients who are in a coma or have other disorders of consciousness due to sudden or non-sudden brain injuries. The study aims to explore whether two treatments, psilocybin and apomorphine, can help improve the level of consciousness in these patients. Psilocybin is a compound found in certain mushrooms, and apomorphine is a medication that can affect brain activity. Both treatments will be given in specific forms: psilocybin as capsules and apomorphine as a solution for infusion.

The purpose of the study is to see if these treatments can help patients become more aware and responsive. During the study, some patients will receive psilocybin, some will receive apomorphine, and others may receive a placebo. The study will observe changes in consciousness levels within a few hours after treatment. The study will also look at other factors like how the pupils react to light and brain activity over a week, as well as the overall health outcome after 90 days.

Participants in the study will be monitored closely to ensure their safety, and any serious side effects will be recorded. The study is expected to continue until the end of 2028, with recruitment starting in early 2024. This research hopes to find new ways to help patients recover from severe brain injuries and improve their quality of life.

]]>